Article: Akzo settles Remeron cases; shuts plant in New Jersey.(United States/Americas)

Akzo Nobel says its Organon pharma unit has agreed to pay $28-million to three U.S. generic drug makers to settle antitrust counterclaims related to Organon's antidepressant mirtazapine, sold under the tradename Remeron. The plaintiffs alleged that Akzo's filing of patent infringement claims delayed the market introduction of generic mirtazapine and violated antitrust laws.

"Akzo Nobel continues to believe that its actions in obtaining and enforcing its intellectual property rights were appropriate," the company says. "However, given the costs and risks of defending these actions, the company took the opportunity to resolve these matters." Akzo says it is also in ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!